Interchangeability Criteria for Levofloxacin-Based Medicinal Products in the Russian Federation
- Авторы: Kocherovets V.I.1,2, Bunyatyan N.D.1,2, Olefir Y.V.1,2, Alyautdin R.N.2, Romanov B.K.2, Prokof’ev A.B.1,2
-
Учреждения:
- Ministry of Public Health of the Russian Federation, I. M. Sechenov First Moscow State Medical University
- Scientific Centre for Expert Evaluation of Medicinal Products (SCEEMP), Ministry of Public Health of the Russian Federation
- Выпуск: Том 50, № 10 (2017)
- Страницы: 684-690
- Раздел: Drugs
- URL: https://ogarev-online.ru/0091-150X/article/view/244459
- DOI: https://doi.org/10.1007/s11094-017-1512-8
- ID: 244459
Цитировать
Аннотация
The present research was aimed at finding informative criteria for regulating the procedure to determine the interchangeability of systemic levofloxacin-based medicinal products (MP) registered in the RF. The chemical and pharmaceutical characteristics of excipients in 26 commercial levofloxacin products (film-coated tablets for internal use) were compared. Their product lines and instructions for medicinal use were also analyzed. It was shown that the compositions of levofloxacin tablets offered on the RF market differed significantly. It was established that the elaboration and implementation of informative criteria for regulating the procedure to determine the interchangeability of levofloxacin-based drugs should benefit the evaluation of drug quality during the determination of the interchangeability for medicinal use.
Ключевые слова
Об авторах
V. Kocherovets
Ministry of Public Health of the Russian Federation, I. M. Sechenov First Moscow State Medical University; Scientific Centre for Expert Evaluation of Medicinal Products (SCEEMP), Ministry of Public Health of the Russian Federation
Email: chem@folium.ru
Россия, Moscow, 119991; Moscow, 127051
N. Bunyatyan
Ministry of Public Health of the Russian Federation, I. M. Sechenov First Moscow State Medical University; Scientific Centre for Expert Evaluation of Medicinal Products (SCEEMP), Ministry of Public Health of the Russian Federation
Email: chem@folium.ru
Россия, Moscow, 119991; Moscow, 127051
Yu. Olefir
Ministry of Public Health of the Russian Federation, I. M. Sechenov First Moscow State Medical University; Scientific Centre for Expert Evaluation of Medicinal Products (SCEEMP), Ministry of Public Health of the Russian Federation
Email: chem@folium.ru
Россия, Moscow, 119991; Moscow, 127051
R. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products (SCEEMP), Ministry of Public Health of the Russian Federation
Email: chem@folium.ru
Россия, Moscow, 127051
B. Romanov
Scientific Centre for Expert Evaluation of Medicinal Products (SCEEMP), Ministry of Public Health of the Russian Federation
Email: chem@folium.ru
Россия, Moscow, 127051
A. Prokof’ev
Ministry of Public Health of the Russian Federation, I. M. Sechenov First Moscow State Medical University; Scientific Centre for Expert Evaluation of Medicinal Products (SCEEMP), Ministry of Public Health of the Russian Federation
Email: chem@folium.ru
Россия, Moscow, 119991; Moscow, 127051
Дополнительные файлы
